Cancer Treatment Today » Cholangiocarcinoma http://cancertreatmenttoday.org Knowledge is Power Thu, 26 Mar 2026 23:39:25 +0000 en-US hourly 1 Primary Sclerosing Cholangitis (PSC) http://cancertreatmenttoday.org/primary-sclerosing-cholangitis-psc/ http://cancertreatmenttoday.org/primary-sclerosing-cholangitis-psc/#comments Tue, 17 Jul 2012 14:33:49 +0000 M Levin, MD http://cancertreatmenttoday.org/?p=3525 Primary sclerosing cholangitis (PSC) is a chronic, liver disease characterized by bile stasis within bile ducts and liver inflammation and fibrosis. It is thought to be an immune mediated, progressive disorder that eventually develops into liver cirrhosis, portal hypertension and hepatic decompensation, in the majority of patients. How does one follow the activity of this disease? Guidelines do not recommend routine MRCP or ERCP to screen for screening for cholangio or hepatocellular(liver) carcinoma. They do recommend these tests for patients with deterioration in their constitutional performance or worsening liver tests. These patients should have these tests to evaluate for a possible chalangiocarcinoma.

]]> http://cancertreatmenttoday.org/primary-sclerosing-cholangitis-psc/feed/ 0 Routine MCP or ERCP Surveillance for Cholagniocarcinoma or Liver Cancer in Patients with Primary Biliary Cirrhosis. http://cancertreatmenttoday.org/routine-m-cp-or-ercp-surveillance-for-cholagniocarcinoma-or-liver-cancer-in-patients-with-primary-biliary-cirrhosis-3/ http://cancertreatmenttoday.org/routine-m-cp-or-ercp-surveillance-for-cholagniocarcinoma-or-liver-cancer-in-patients-with-primary-biliary-cirrhosis-3/#comments Wed, 20 Jun 2012 22:09:44 +0000 M Levin, MD http://cancertreatmenttoday.org/?page_id=1381 Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease characterized by inflammation and fibrosis of both intrahepatic and extrahepatic bile ducts. It is thoughtto be an immune mediated, progressive disorder that eventually develops into cirrhosis, portal hypertension and hepatic decompensation, in the majority of patients. Guidelines do not recommend routine MRCP or ERCP to screen for chalngiocarcinoma or hepatocellular carcinoma. They do recommend that patients with deterioration in their constitutional performance status or liver biochemical-related parameters should undergo an evaluation for CCA.

Read the Professional version here.

]]> http://cancertreatmenttoday.org/routine-m-cp-or-ercp-surveillance-for-cholagniocarcinoma-or-liver-cancer-in-patients-with-primary-biliary-cirrhosis-3/feed/ 0